Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

Oral step-down therapy for infective endocarditis

Background: The standard of care for IE has been a prolonged course of IV antibiotics. Recent literature has suggested that oral antibiotics might be a safe and effective step-down therapy for IE.

Dr. Elizabeth Yoo, division of hospital medicine, Mount Sinai Health System, New York

Dr. Elizabeth Yoo

Study design: Systematic review.

Setting: Literature review in October 2019, with update in February 2020, consisting of 21 observational studies and 3 randomized controlled trials.

Synopsis: Three RCTs and 21 observational studies were reviewed, with a focus on the effectiveness of antibiotics administered orally for part of the therapeutic course for IE patients. Patients included in the study had left- or right-sided IE. Pathogens included viridians streptococci, staphylococci, and enterococci, with a minority of patients infected with methicillin-resistant Staphylococcus aureus. Treatment regimens included beta-lactams, linezolid, fluoroquinolones, trimethoprim-sulfamethoxazole, or clindamycin, with or without rifampin.

In studies wherein IV antibiotics alone were compared with IV antibiotics with oral step-down therapy, there was no difference in clinical cure rate. Those given oral step-down therapy had a statistically significant lower mortality rate than patients who received only IV therapy.

Limitations include inconclusive data regarding duration of IV lead-in therapy, with the variance before conversion to oral antibiotics amongst the studies ranging from 0 to 24 days. The limited number of patients with MRSA infections makes it difficult to draw conclusions regarding this particular pathogen.

Bottom line: Highly orally bioavailable antibiotics should be considered for patients with IE who have cleared bacteremia and achieved clinical stability with IV regimens.

Citation: Spellberg B et al. Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review. JAMA Intern Med. 2020;180(5):769-77. doi: 10.1001/jamainternmed.2020.0555.

Dr. Yoo is a hospitalist in the Division of Hospital Medicine, Mount Sinai Health System, New York.

  • 1

    Oral step-down therapy for infective endocarditis

    December 13, 2021

  • 1

    Reflecting on 2021, looking forward to 2022

    December 10, 2021

  • 1

    Anticoagulant choice in antiphospholipid syndrome–associated thrombosis

    December 10, 2021

  • 1

    Chronically interrupted: The importance of communication with patient and family during the COVID-19 pandemic

    December 9, 2021

  • AMA, hospital group sue federal government over surprise billing law

    December 9, 2021

  • 1

    Apixaban a reasonable alternative to warfarin in patients with severe renal impairment

    December 9, 2021

  • 1

    New data on rare myocarditis after COVID-19 vaccination

    December 8, 2021

  • 1

    The top pediatric hospital medicine articles of 2020

    December 8, 2021

  • 1

    Timing of initiation of renal-replacement therapy in acute kidney injury

    December 8, 2021

  • 1

    Is mindfulness key to helping physicians with mental health?

    December 8, 2021

1 … 103 104 105 106 107 … 984
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • Cookie Preferences